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Management of device-related malignant sarcomaArash Khamooshian, MD,* Theo J. Klinkenberg, MD,* Alexander H. Maass, MD, PhD,†
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From the *Department of Cardio-Thoracic Surgery, Thorax Center, University of Groningen, University
Medical Center Groningen, Groningen, The Netherlands, and †Department of Cardiology, Thorax Center,
University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.Introduction
With the globally increasing life expectancy and improved
outcome of congenital heart disease, the number of cardiac
device implantations is increasing steadily.1,2 A prolonged
pacemaker (PM) therapy period is associated with potential
long-term complications. Thereby battery and electrode
longevity have not improved in the past decades, leading to
recurrent device and electrode replacements. The combina-
tion of an increased PM indication and life expectancy
possibly aggravates this effect.3 An increased frequency of
device and electrode replacements leads to higher complica-
tion rates than de novo implantations.4 A rare complication
after PM implantation is the development of malignant sar-
comas. Previous studies demonstrated a slightly higher risk
of cancer in PM recipients.5 In this report we present a case
of an undifferentiated pleomorphic sarcoma surrounding
PM electrodes during prolonged PM therapy and recurrent
replacements. To our knowledge, this has not been reported
so far.Case report
A43-year-oldman presented 8months after PMupgradewith
a growing mass located below his PM pocket scar tissue. A
DDD PM (dual-chamber atrioventricular [AV] sequential
pacing) was implanted in 1989 for treatment of intermittent
AV block of unknown origin. The PM was inserted in the
left deltopectoral groove, and the electrodes were introduced
via the left subclavian vein. The leads were revised after 1
week owing to atrial lead dislodgement. End of life necessi-
tated PM device replacement in 1999 and 2005, combined
with atrial lead repair owing to an isolation defect. In October
2012 device replacement was again indicated. Preoperative
examination revealed a diminished left ventricular (LV) func-
tion of 35%,most likely caused by permanent right ventricularKEYWORDS Sarcoma; Pacemaker; Resynchronization therapy; Malignancy;
Pacemaker leads (Heart Rhythm Case Reports 2017;3:373–376)
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heart failure protocol, which failed to improve his cardiac
function. The patient was planned for biventricular pacing
therapy according to the ESC guidelines (class I indication).6
During evaluation for additional lead placement, no signs of
coronary artery disease were present on the coronary angio-
gram and venous levophase demonstrated a suitable coronary
sinus anatomy. A total occlusion of the left brachiocephalic
vein on venous angiogram prevented placement of a right-
sided coronary sinus lead, owing to the high risk of vena
cava superior syndrome. Extraction of the left-sided system
with placement of new leads through the existing canal was
considered. All therapeutic options were discussed with the
patient. The risk-to-beneﬁt ratio of epicardial LV lead place-
ment was found superior to total system extraction and an
epicardial LV lead was placed by video-assisted thoracic sur-
gery.7 The postoperative recovery was uneventful and the LV
ejection fraction increased to 45% at 6 months follow-up.
Swelling of the PM pocket was ﬁrst noticed in the summer
of 2013. A large, ﬁrm mass was palpable cephalad of the PM
pocket (Figure 1A). No signs of infection were present and
the patient experienced no noticeable discomfort. Ultraso-
nography revealed a lobulated, hypoechogenic, solid lesion
of 23! 15! 78 mm with sharply deﬁned edges, encasing
the PM leads. Needle biopsy revealed pleomorphic malig-
nant cells with hyperchromatic, polymorphic nuclei.
Immunohistochemistry demonstrated an undifferentiated
pleomorphic sarcoma. A computed tomography scan was
performed for staging purposes and demonstrated a
30-mm round nodule in the left shoulder region without pul-
monary metastasis or mediastinal/hilar lymphadenopathy
(Figure 1B). Radical tumor resection was feasible according
to the multidisciplinary sarcoma team, although it yielded
some challenges: (1) tumor spill had to be prevented; (2)
the patient’s rhythm had to be secured because he was PM
dependent; and (3) a large defect after resection had to be re-
constructed. To prevent tumor spill, the PM pocket was ap-
proached caudally and a successful PM removal was
performed. Conventional PM replacement and lead discon-
nection would have caused tumor damage and spill. The
advantage of the recently placed epicardial LV lead was the
intrathoracic approach for the PM connection; hence no signs




 Sarcomas around pacemaker sites are a rare ﬁnding.
 One should be aware of possible malignancies when
swelling occurs in the proximity of pacemakers.
 Sarcoma treatment in dedicated centers with a
multidisciplinary approach is highly recommended.
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needed. As stated earlier, introduction of a new right-sided
transvenous PM lead was considered hazardous. A new
single-chamber PM was placed in the rectus abdominis mus-
cle with a lead extension subcutaneously tunneled to the
epicardial LV lead. The device was programmed to VVI-R
mode. The old right atrial and ventricular leads were cut off
and capped. A radical tumor resection including the encaged
old PM leads and part of the greater pectoral and deltoid mus-
cle was carried out without tumor spill (Figure 2A–C). The
caudal incision was extended by a 12 ! 8-cm horseshoe-
like incision containing a skin ﬂap for reconstruction
purposes (Figure 2D). The defect was reconstructed using
the remaining greater pectoral muscle. Pathology conﬁrmed
undifferentiated pleomorphic sarcoma with tumor-free mar-
gins. Postoperative recovery was uneventful and the patient
was discharged on the third postoperative day. A 60-Gy adju-
vant radiotherapy was provided because a marginal resection
was performed.Figure 1 A: A large, ﬁrm mass situated beneath the scar tissue, cranially
of the pacemaker pocket. No signs of infection were present. The tumor is
marked prior to surgery. B: Computed tomography scan demonstrating a
30-mm round nodus in the left shoulder region without pulmonary metastasis
or mediastinal or hilar lymphadenopathy.Discussion
In this report we describe a rare case of malignant sarcoma
surrounding a frequently renewed PM. Some challenges
had to be overcome for safe resection. A multidisciplinary
team determined treatment strategy. The latest (epicardial)
PM lead and a new PM in the rectus abdominis position
were used to secure the patient’s rhythm prior to resection.
Old PM leads were cut off and capped. The tumor was
resected successfully and the defect reconstructed using a
rotation ﬂap. Epicardial LV leads are a safe alternative for
intravascular leads. In patients with sinus rhythm, PM syn-
drome is a possible complication of single-chamber pacing.
This is, however, not common in patients with congenital
AV block or acquired AV block in young patients, as they
are used to AV dyssynchrony. LV-only pacing might cause
reverse dyssynchrony compared with right ventricular–only
pacing. However, evidence on LV-only vs biventricular pac-
ing suggests equality if not superiority of LV-only pacing. In
our patient, no symptoms of PM syndrome were observed
and LV function is preserved at long-term follow-up.
Sarcomas are a rare and heterogeneous group of malignant
tumors of mesenchymal origin; they comprise less than 1% of
all adult malignancies.8,9 The majority (approximately 80%)
originate from soft tissue of the extremities.10 In a large retro-
spective registry a higher incidence of malignancies was de-
tected in patients with PM implants, although no excess riskwas found for sarcomas.5 The most common clinical presen-
tation is a gradually enlarging, painless mass. Owing to tumor
progression, pain and paresthesia are frequently present,
caused by compression. Although associated or predisposing
factors have been identiﬁed, most sarcoma cases have no
clearly deﬁned etiology and are thought to arise de novo.
Possible inﬂuencing factors are radiation or chemotherapy,
chemical carcinogens, chronic irritation, and genetic predis-
position.11 Also, silicone implants accompanied by chronic
inﬂammation have been linked to sarcomas.12 This possibly
suggests a causal relationship between inﬂammation or
injury and sarcomas, especially in patients with long-term
PM dependency and multiple lead or PM device revisions.
The mechanism of tumor formation owing to chronic irrita-
tion or tissue–metal contact has not yet been clariﬁed. The
relationship between titanium compounds and malignancies
has been reported earlier, however. In rat models, inhaled
titanium dioxide has the potential to enhance lung malig-
nancies.13 However, this is based on titanium nanoparticles
either inhaled or from wear and tear of metal-on-metal
prosthesis. This is not the case in pacemakers.
Figure 2 A, B: Radical tumor resection including the encaged pacemaker leads and part of the greater pectoral and deltoid muscle. Tumor spill was avoided.
C: Tumor with encaged pacemaker leads post resection. D: Extension of the caudal incision by a 12! 8-cm horseshoe-like incision containing a skin ﬂap for
reconstruction purposes.
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effect of electromagnetic ﬁelds caused by PM devices. This
is speculative, since large studies of long-term and high-
power magnetic ﬁelds in mice did not show an increase in
incidence of malignancy.14 Despite the lack of evidence in
animal studies, a weak promoting effect in humans under
speciﬁc conditions cannot be ruled out.15
Modern medical practice is composed of high-end care
with state-of-the-art treatment strategies based on evidence-
based medicine. Specialized multidisciplinary teams are
required to provide the best possible care for rare conditions.
To ensure correct diagnosis and optimize treatment planning
and outcome, sarcomas should be treated in dedicated sar-
coma centers with a multidisciplinary approach. Radical
resection of sarcomas is complex and technically demanding.
Treatment in an expert center is safe and markedly improves
patient survival. In this present case, a signiﬁcant amount of
time was spent on safety planning: (1) ensuring cardiac pac-
ing, (2) performing a radical resection and preventing tumor
spill, and (3) surgically reconstructing the defect to ensure
primary wound healing and to prevent delay in adjuvant
radiotherapy.
In conclusion, sarcomas surrounding pacemakers are inci-
dental ﬁndings. Literature provides no signiﬁcant association
between pacemakers and malignant sarcomas. Nevertheless,
physicians should be aware of possible malignancies when
swelling occurs in the proximity of pacemakers, especially
because PM implantation and replacements are becoming
more frequent. Postoperative follow-up after implantationshould therefore include careful inspection of PM pockets.
In addition, the authors emphasize the beneﬁt of dedicated
and specialized care for patients with neoplasms near
PM pockets. Referral to a dedicated center is highly
recommended.References
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